Biotech Values

[DewDiligence]

IDIX is having its second consecutive day of double-digit gains.

At the risk of sounding like a broken record, I recommend that anyone interested in the antiviral space listen to IDIX’s JPM webcast from Tuesday—or read the stuff I’ve posted about it. IDIX had a big setback in 2007, but now they’re back!

Actually, it may be more accurate to say that IDIX was never really “out” inasmuch as they are one of the few antiviral companies with a bona fide drug-discovery engine. They’ve had backup compounds to NM283 for some time, but they didn’t talk about them until now.